Bio-Key International Files 8-K for Q1 2026 Results
Ticker: BKYI · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001019034
Sentiment: neutral
Topics: financial-reporting, results-of-operations
TL;DR
Bio-Key International dropped its Q1 2026 results on 8-K, check the financials.
AI Summary
Bio-Key International, Inc. filed an 8-K on March 31, 2026, reporting its results of operations and financial condition for the period ending March 31, 2026. The filing includes financial statements and exhibits, with the primary document being the 8-K itself in iXBRL format.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Bio-Key International, Inc., crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing (8-K) and does not inherently contain new material risks.
Key Players & Entities
- BIO KEY INTERNATIONAL INC (company) — Filer
- 0001019034 (company) — CIK Number
- 2026-03-31 (date) — Filing Date and Period of Report
FAQ
What specific financial results are reported in this 8-K filing?
The filing reports on the 'Results of Operations and Financial Condition' for the period ending March 31, 2026, but the specific financial figures are detailed within the attached documents, not summarized in the main 8-K text provided.
What is the purpose of an 8-K filing?
An 8-K filing is a report of unscheduled material events or corporate changes at a company, such as the results of operations and financial condition as reported by Bio-Key International.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 31, 2026, at 08:45:10.
What are the main documents included in this filing?
The filing includes the main FORM 8-K document in iXBRL format, EXHIBIT 99.1, and various XBRL data files (schema, definition, label, presentation, instance).
Where is Bio-Key International, Inc. located?
The company's mailing and business address is 101 CRAWFORDS CORNER RD SUITE 4116 HOLMDEL NJ 07733.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2026-03-31 08:45:10
Filing Documents
- bkyi20260331_8k.htm (8-K) — 29KB
- ex_939585.htm (EX-99.1) — 289KB
- biokeylogo.jpg (GRAPHIC) — 11KB
- 0001437749-26-010506.txt ( ) — 485KB
- bkyi-20260331.xsd (EX-101.SCH) — 3KB
- bkyi-20260331_def.xml (EX-101.DEF) — 12KB
- bkyi-20260331_lab.xml (EX-101.LAB) — 15KB
- bkyi-20260331_pre.xml (EX-101.PRE) — 12KB
- bkyi20260331_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 31,2026, BIO-key International, Inc. (the "Company") issued a press release announcing its financial results for its fourth quarter and year ending December 31, 2025. A copy of the press release issued by the Company on March 31, 2026, is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
01. Financial Statements, Pro Forma Financial Information and Exhibit
Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibit. (d) Exhibits. The following exhibit is furnished herewith: 99.1 Press Release, dated March 31, 2026, issued by the Company. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-KEY INTERNATIONAL, INC. Date: March 31,2026 By: /s/ Cecilia C. Welch Cecilia C. Welch Chief Financial Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated March 31, 2026 issued by the Company.